Transcriptomics Technologies Market, By Technology (Microarrays, PCR, Gene Regulation Technologies, Next Generation Sequencing), By Application (Clinical Diagnostics, Drug Discovery & Research, Bioinformatics, Comparative Transcriptomics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Jul 2020

Code : CMI3989

Pages :150

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

Global Transcriptomics Technologies Market: Drivers

Approval and launch of microarrays is expected to propel growth of the global transcriptomics technologies market over the forecast period. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.

Moreover, initiatives to advance personalized medicine are also expected to aid in growth of the market. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database.

Global Transcriptomics Technologies Market: Restraints

Lack of efficient data analysis tools is expected to hinder growth of the market. With increasing technological advances, there has been a rising concern about data complexity post analysis of transcripts through sequencing platforms. Complex data management is one of the major limitations faced in transcriptome research. The data complexity increases with advances in the subsequent RNA analysis methodologies.

Moreover, complex processes involved in isolation of RNA from the tissue of interest are also expected to limit the market growth.

Global Transcriptomics Technologies Market: Opportunities

Increasing prevalence of cancer is expected to offer lucrative growth opportunities for players in the global transcriptomics technologies market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, development of new technologies is also expected to aid in growth of the market. For instance, in December 2019, PathogenDx, Inc. was awarded two US Patents for Tandem PCR + Microarray Hybridisation technology.